Novo Nordisk’s once-weekly semaglutide diabetes injection has attracted widespread attention for its effects on appetite and body weight. Many people first hear about it in the context of weight loss, even though this formulation is registered in Singapore for type 2 diabetes rather than weight management.
If you are considering treatment primarily to lose weight, it is helpful to understand how this injection compares with options specifically registered for weight management, including another semaglutide formulation and Eli Lilly’s once-weekly tirzepatide injection. The most suitable option depends on your health, previous treatment and what you hope to achieve.
This guide explains how the diabetes formulation works, what weight-loss results are realistic, and what to expect from treatment, including doses, costs and side effects.
Learn more about Novo Nordisk’s once-weekly 2.4 mg semaglutide treatment for weight management at https://edwinlimclinic.sg/wegovy-weight-loss-singapore-guide/
Learn more about Eli Lilly’s once-weekly tirzepatide treatment at https://edwinlimclinic.sg/mounjaro-tirzepatide-injection-for-weight-loss-in-singapore-doctors-comprehensive-guide/
Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. The weekly diabetes formulation is registered in Singapore for adults whose type 2 diabetes is not adequately controlled, alongside diet and exercise. It may be prescribed with other diabetes medicines or on its own when metformin is unsuitable because of intolerance or a contraindication.
Its Singapore indications also include reducing certain cardiovascular risks in adults with type 2 diabetes and established cardiovascular disease, and certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease. The evidence behind these uses is explained below.
The medicine is supplied as an injection pen and requires a prescription.
Semaglutide acts on GLP-1 receptors, including those involved in appetite regulation in the brain. This can help you feel less hungry and more satisfied with smaller meals, making it easier to reduce food intake. It can also slow stomach emptying, particularly in the early period after eating, which may contribute to feeling full.
These effects support weight loss by changing appetite and how much you eat. The injection does not directly melt fat or target one area of the body, and your response will also depend on factors such as eating patterns, activity and the dose you can tolerate.
Semaglutide also helps regulate blood sugar. When blood sugar is elevated, it encourages the pancreas to release insulin and reduces glucagon, a hormone that prompts the liver to release stored glucose. This is why the medicine can be useful when someone has both type 2 diabetes and excess weight.
Weight loss can be a useful effect of treatment, particularly when a person has both type 2 diabetes and excess weight. However, prescribing this diabetes formulation solely for weight loss falls outside its registered indication. This is called off-label use.
If off-label treatment is being considered, we explain the reason for recommending it, discuss the benefits and risks, and review alternatives registered for weight management. This helps you understand how the proposed treatment fits your health needs.
If you do not have diabetes, we first assess whether medication is appropriate for your weight-related health needs and discuss the options registered for weight management. Prediabetes or excess weight alone does not automatically make this particular formulation the right choice.
Compare the available weekly treatments at https://edwinlimclinic.sg/weight-loss-injections-singapore-guide/
Appetite, blood sugar and body weight do not necessarily change at the same pace. Reviewing each of these helps us understand your response rather than relying on a single weight reading.
Some people notice changes in appetite during the early weeks, while others find the effect less obvious at the starting dose. The first four weeks are used to introduce treatment and assess side effects before the usual dose increase. A small change on the scales during this period does not, by itself, show whether treatment will be helpful over time.
We review your weight trend over subsequent visits. If you have diabetes, blood sugar readings can help assess earlier changes, while HbA1c, a blood test reflecting average blood sugar over roughly three months, provides a longer-term picture. There is no fixed week by which everyone should lose a particular amount of weight.
SUSTAIN-1 studied adults with type 2 diabetes over 30 weeks. Average starting weight was approximately 92 kg. The average reductions in body weight were:
|
Treatment |
Average Weight Reduction at 30 Weeks |
|---|---|
|
Semaglutide 0.5 mg weekly |
3.7 kg |
|
Semaglutide 1 mg weekly |
4.5 kg |
|
Placebo |
1.0 kg |
These averages describe people with type 2 diabetes in this particular trial. Your result may differ, and the figures are not a forecast for someone without diabetes. Evidence from higher-dose obesity treatment is discussed in our separate weight-management guide.
If your weight is not changing, we look at the trend alongside appetite, food intake, side effects and, when relevant, blood sugar results. For diabetes treatment, better glucose control remains important even when weight loss is modest.
The review may also cover how consistently injections are taken, whether eating patterns have changed and whether the current treatment still suits your goals. Depending on the findings, the next step may involve changes to nutrition, a dose review or a discussion of other treatment options.
If you first heard about weekly injections through the diabetes formulation, you may be wondering whether another option would better suit your weight-loss goals. The main differences are the approved uses, dose schedules and evidence for each treatment.
Both formulations contain semaglutide, but they have different approved uses and dose schedules. The diabetes injection discussed here uses the 0.25 mg, 0.5 mg and 1 mg schedule. The weight-management formulation follows a different dose schedule, with 2.4 mg weekly used in its pivotal obesity trials.
If weight loss is your main goal, we can explain whether the weight-management formulation is more appropriate. Its higher-dose trial results should not be assumed to apply to the diabetes doses. A switch requires a review of your prescription and treatment history.
Read more about Novo Nordisk’s weekly semaglutide weight-management treatment, including the separate higher-dose option, at https://edwinlimclinic.sg/wegovy-weight-loss-singapore-guide/
Eli Lilly’s tirzepatide is another weekly option. The Singapore-registered KwikPen has indications for type 2 diabetes and adult weight management under its respective prescribing conditions. It acts on both GIP and GLP-1 receptors, which are involved in appetite and blood sugar regulation, whereas semaglutide acts on the GLP-1 receptor. Their milligram doses are not equivalent.
SURPASS-2 directly compared semaglutide 1 mg weekly with tirzepatide in adults with type 2 diabetes taking metformin. At 40 weeks, average weight reductions were about 5.7 kg with semaglutide and 7.6 kg, 9.3 kg and 11.2 kg with tirzepatide 5 mg, 10 mg and 15 mg respectively. The semaglutide result differs from SUSTAIN-1 because these were separate trials with different participants, background treatment and durations. This comparison does not establish the same differences in people without diabetes or against higher-dose semaglutide.
The trial helps inform the discussion, but choosing a medicine also involves your treatment needs, previous response, side effects and cost.
Learn more about Eli Lilly’s once-weekly tirzepatide treatment at https://edwinlimclinic.sg/mounjaro-tirzepatide-injection-for-weight-loss-in-singapore-doctors-comprehensive-guide/
Suitability depends on the reason for treatment, your medical history and your current medicines. For diabetes treatment, we consider blood sugar control, previous treatment and any associated heart or kidney disease. For weight management, we also discuss your weight history, eating patterns and the effect of weight on your health.
At our clinic, the initial assessment includes body mass index (BMI), which relates weight to height, as well as blood pressure, medical history and current medication. Please bring recent test results and details of any previous weight-management treatment, including the dose used and any side effects. This helps us understand what has already been tried.
Blood tests are ordered when clinically indicated rather than as an automatic requirement for every weight-management consultation. If you have diabetes, we may review your HbA1c and kidney function and the monitoring arranged by your usual doctor. Treatment should fit into your wider diabetes care.
Treatment begins at a low dose so that we can assess how you respond and whether you experience side effects before increasing it. The usual Singapore prescribing schedule is outlined below.
|
Weekly Dose |
Usual Stage |
Purpose |
|---|---|---|
|
0.25 mg |
First four weeks |
Starting dose to introduce treatment. |
|
0.5 mg |
After the first four weeks |
Next dose in the usual treatment schedule. |
|
1 mg |
After at least four weeks at 0.5 mg, if needed |
An increase considered when further blood sugar control is required. |
The 0.25 mg dose is intended for starting treatment. Whether you progress to 1 mg depends on your blood sugar control and how well you tolerate the medicine. Let us know about persistent nausea, vomiting or difficulty eating before any planned increase, and follow the prescribed schedule rather than adjusting the dose yourself.
The medicine is injected under the skin of the abdomen, thigh or upper arm, with injection sites rotated. It is taken once weekly and can be administered with or without food. Our clinic provides injection training so that you understand how to use the prescribed pen before continuing treatment at home.
Follow the instructions for the pen supplied to you, including using a new needle for each injection. If you are unsure whether an injection was delivered correctly, contact the clinic before taking another dose.
The first follow-up is arranged after you complete the first pen. We review your response and any side effects before deciding whether to continue or change treatment. If progress is satisfactory and treatment is stable and well tolerated, reviews may subsequently be spaced three to four months apart. Earlier review may be needed during dose changes, if symptoms occur or for diabetes monitoring.
Patients can WhatsApp the clinic with questions between visits. Urgent symptoms require prompt medical assessment rather than waiting for a message reply or the next scheduled appointment.
Learn more about Dr Edwin Lim’s personalised medical weight-loss programme at https://edwinlimclinic.sg/personalised-medical-weight-loss-program-in-singapore/
Consultations are available at Changi City Point and Lucky Plaza in Orchard. Find our clinic locations and contact details at https://edwinlimclinic.sg/contact-number/
Nausea, vomiting, diarrhoea, constipation and bloating can occur. Smaller meals, sufficient fluids and avoiding foods that aggravate symptoms may help. Contact the clinic if symptoms persist or affect eating and drinking; significant symptoms should be reviewed before increasing the dose.
Tell your doctor about previous pancreatitis, gallbladder problems, severe digestive symptoms, allergies, kidney or liver disease, and all medicines you use. Also mention any personal or family history of thyroid cancer, particularly medullary thyroid cancer, or a diagnosis of multiple endocrine neoplasia type 2, known as MEN2. MEN2 is an inherited condition associated with endocrine gland tumours. These details help us assess risk and plan monitoring.
Using semaglutide with insulin or certain diabetes tablets can increase the risk of low blood sugar. Your doctor may need to adjust those medicines. Semaglutide is not a replacement for insulin, and you should not stop insulin yourself.
People with existing diabetic retinopathy may need closer eye monitoring, particularly when blood sugar improves rapidly. Tell your doctor about any previous diabetes-related eye disease.
A separate condition, non-arteritic anterior ischaemic optic neuropathy, or NAION, affects blood supply to the optic nerve. The European Medicines Agency classifies NAION as a very rare side effect of semaglutide. Sudden loss of vision or rapidly worsening eyesight needs urgent assessment, even if there is no pain.
Semaglutide should not be used during pregnancy or breastfeeding and should be stopped at least two months before a planned pregnancy. Discuss this in advance so that appropriate alternative care can be arranged, particularly if you have diabetes.
Tell the team managing any operation or procedure involving sedation that you use semaglutide. Its effect on stomach emptying may affect their preparation instructions. Follow the individual plan they provide.
Persistent severe abdominal pain can be a sign of pancreatitis, which is inflammation of the pancreas. Upper abdominal pain with fever or jaundice may indicate a gallbladder or bile duct problem. These symptoms need assessment rather than being dismissed as ordinary digestive side effects.
Seek prompt medical help for these symptoms. Breathing difficulty, collapse or severe allergic symptoms require emergency care.
Reduced appetite can make it easier to eat less, but it is still important to eat adequately. Include protein-containing foods such as fish, eggs, lean meat, tofu or dairy, alongside vegetables and other nutritious foods. Very restrictive eating can make it harder to meet nutritional needs.
Resistance exercise, adjusted to your fitness and health, helps support muscle strength during weight loss. If you have kidney disease, discuss protein intake with your treating clinician rather than following a generic high-protein diet. Report persistent weakness or difficulty eating so that your plan can be reviewed.
Appetite can return after treatment stops, and weight regain is possible. In the STEP-1 extension, participants regained about two-thirds of their previous weight loss over the year after semaglutide and the study’s lifestyle intervention were withdrawn. That study used the 2.4 mg obesity regimen; the figure is not a prediction for people taking the lower-dose diabetes formulation.
Before stopping, agree on a plan for meals, physical activity, weight monitoring and follow-up. If weight begins to rise consistently, review the plan early rather than waiting until most of the lost weight returns. If you have diabetes, stopping also requires consideration of blood sugar control and whether another treatment is needed. Reducing the dose gradually has not been established as a reliable way to prevent weight regain.
For some people with type 2 diabetes, semaglutide can help reduce the risk of serious heart or kidney complications. The evidence comes from studies of patients with particular health risks, so it is important to understand whom the findings apply to.
SUSTAIN-6 studied weekly semaglutide at 0.5 mg or 1 mg in adults with type 2 diabetes and high cardiovascular risk. It found fewer major cardiovascular events, meaning heart attack, stroke or death from cardiovascular causes, with semaglutide than with placebo.
FLOW studied 1 mg weekly in adults with type 2 diabetes and chronic kidney disease. Researchers assessed a combined measure that included kidney failure, a substantial decline in kidney function, or death from kidney-related or cardiovascular causes. This outcome occurred less often with semaglutide than with placebo.
These findings can help guide treatment for people with diabetes and the relevant health risks. They do not establish the same benefits for everyone seeking weight loss. Semaglutide is used as part of a wider care plan, alongside other treatments where needed.
No. Semaglutide is a GLP-1 receptor agonist. It helps regulate blood sugar through a different mechanism and does not replace prescribed insulin. Your doctor will explain how it fits with your existing diabetes medicines.
No. A prescription and appropriate medical assessment are required. At our clinic, the initial consultation takes place in person. Obtain prescription medication through a licensed healthcare provider or pharmacy rather than informal sellers.
If you remember within five days, take the missed dose as soon as possible. If more than five days have passed, skip it and continue on your usual weekly day. Do not double the dose. If you have missed several doses, ask your doctor how to restart.
Switching may be considered after a medical review. Bring the name of the medicine, your current dose, the date of your last injection and any side effects. The doctor will decide the timing and starting dose; there is no simple milligram-for-milligram conversion between semaglutide and tirzepatide. Do not overlap treatments unless specifically directed by your prescriber.
There is no single course length that suits everyone. Your doctor will review the reason for treatment, its benefit, tolerability and alternatives. If it is prescribed for diabetes, reaching a particular weight does not by itself mean the medicine is no longer needed.
Zh